XTL Biopharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through March 6 To Regain Compliance

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. This Nasdaq determination was based on (i) the Company's Form 6-K, dated December 30, 2025, that included financial information for the period ended June 30, 2025, and which reported stockholders' equity deficit of $47,000, and (ii) that the Company does not meet the alternatives of market value of listed securities or net income from continuing operations as of January 20, 2026.

The Nasdaq notification letter does not result in the immediate delisting of the Company's American Depositary Shares ("ADSs"), and the ADSs will continue to trade uninterrupted under the symbol "XTLB". In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days, or until March 6, 2026, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from receipt of the Notification Letter to evidence compliance.